Reported about 12 hours ago
Acadian Asset Management LLC has increased its investment in Aclaris Therapeutics, Inc. (ACRS) by 25.9%, owning 2.03% of the company after acquiring 451,044 shares. Despite past challenges, Aclaris is gaining attention as it prepares to present promising Phase 2a trial results for its atopic dermatitis treatment, ATI-2138, at the upcoming 2025 EADV Congress in Paris, indicating potential for future success.
Source: YAHOO